Clinical and Immunogenetic Characterization of Giant Cell Arteritis (GCA) and Polymyalgia Rheumatica (PMR)
UK GCA Consortium: Clinical and Immunogenetic Characterization of Giant Cell Arteritis (GCA) and Polymyalgia Rheumatica (PMR)
University of Leeds
4,500 participants
Jun 10, 2005
OBSERVATIONAL
Conditions
Summary
A multi-centre observational study recruiting prospective and retrospective cohorts of patients with polymyalgia rheumatica (PMR) and giant cell arteritis (GCA). The primary aim is to find genetic determinants of GCA and PMR susceptibility, in order to yield novel insights into disease pathogenesis. A subset of the retrospective cohort is also enrolled in a post-marketing surveillance registry of patients eligible for, or receiving tocilizumab, to treat their relapsing or refractory GCA.
Eligibility
Inclusion Criteria3
- Willing to self-identify an ethnic group, such as Caucasian, Asian, Afro-Caribbean.
- Have a firm clinical diagnosis of GCA or PMR, or (for patients identified prospectively) GCA or PMR should be more likely than any alternative explanation for the patient's symptoms.
- Able and willing to give informed consent. Patients will be 50 years of age or over, unless both biopsy-proven and a clinically classical case of GCA.
Exclusion Criteria1
- Patient unwilling or unable to give fully informed consent.
Interested in this trial?
Get notified about updates and connect with the research team.
Locations(76)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT04102930